Skip to content

Search

Bronchiectasis Research for Improving Lung Health outcomes and Treatment (BRIGHT)

This prospective, longitudinal cohort study will examine airway sputum, lung function, and clinical surveillance data of children with bronchiectasis attending Perth Children’s Hospital.

FINGERPRINT: FINdinG Early markers of Respiratory disease for survivors of PReterm birth which IdeNtify Treatable traits

This research project will investigate the traits of preterm lung disease, looking into the long-term lung health of children born preterm, aiming to identify traits that could help guide better treatments in the future.

PELICAN: Prematurity’s Effects on the Lungs in Children and Adults Network

The PELICAN (Prematurity’s Effects on the Lungs in Children and Adults Network) Clinical Research Collaboration was launched by the European Respiratory Society (ERS) in 2020

The Impact of Modulator therapy from Early life on lung health trajectories in Cystic Fibrosis (TIME-CF)

Cystic fibrosis is an inherited condition that results in chronic lung disease. In recent years, a new type of medication called CFTR modulators has become available.

Western Australia Paediatric Bronchiectasis Cohort

Bronchiectasis is a chronic lung disease that impairs quality of life and reduces life expectancy.

Cohort profile: The WAACHS Linked Data Study

Despite the volume of accumulating knowledge from prospective Aboriginal cohort studies, longitudinal data describing developmental trajectories in health and well-being is limited.

Pandemic preparedness needs for children with rare diseases and their families: A perspective of COVID-19 experiences

People living with rare diseases had a high risk of negative health outcomes due to COVID-19. Pandemic preparedness will ensure best practice procedures and optimal outcomes during future pandemic events. This paper sought to understand the needs of children with rare diseases during the COVID-19 pandemic to inform preparation for future pandemic and disaster events. First, impacts and outcomes from the COVID-19 pandemic on people living with rare disease were identified in the literature.

Transcriptomic analysis of primary nasal epithelial cells reveals altered interferon signalling in preterm birth survivors at one year of age

Many survivors of preterm birth (<37 weeks gestation) have lifelong respiratory deficits, the drivers of which remain unknown. Influencers of pathophysiological outcomes are often detectable at the gene level and pinpointing these differences can help guide targeted research and interventions. This study provides the first transcriptomic analysis of primary nasal airway epithelial cells in survivors of preterm birth at approximately 1 year of age.

Improving screening in a paediatric cohort for cystic fibrosis-related diabetes: A quality improvement project

André Schultz MBChB, PhD, FRACP Head, BREATH Team Head, BREATH Team Prof André Schultz is the Head, BREATH Team at The Kids Research Institute

Which reference equation should we use for interpreting spirometry values for First Nations Australians? A cross-sectional study

To evaluate the suitability of the Global Lung Function Initiative (GLI)-2012 other/mixed and GLI-2022 global reference equations for evaluating the respiratory capacity of First Nations Australians.